Ysios, J&J back €11.5M round in Aelix to fund trials of HIV treatment

Nick Paul Taylor

Therapeutics has raised €11.5 million ($ 12.6 million) to advance a therapeutic HIV candidate to clinical proof of concept. Capital, Johnson & Johnson and others backed the , having been persuaded that 's immunotherapy has the potential to be a functional cure for HIV.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS